'Bmd' diaporamas de présentation

BMD Monitoring

Mahtab Niroomand M.D. Assistant Professor of Endocrinology SBMU Research Institute of Endocrine Sciences June, 2013. BMD Monitoring. Outline. BMD monitoring in osteoporotic patients BMD monitoring in non-Osteoporotic patients Preferred Site for Monitoring Guidelines. Introduction.

847 views • 69 slides

Clinical Cases

Clinical Cases. Akbar S oltani . MD .Endocrinologist Tehran University of Medical Sciences (TUMS) Evidence-Based Medicine Research Center Shariati Hospita l www.ebm.ir. Approach to declining BMD. Up-To-Date. Hypothetical low risk scenario.

649 views • 64 slides

Assessing Outcomes and Safety

Assessing Outcomes and Safety. Steven R. Cummings, MD Director, SF Coordinating Center. Outline: Outcomes. Primary and secondary aims Composite outcomes Surrogate markers Adverse experiences. Morbone. A company wants help designing a trial of Morbone new treatment for osteoporosis

670 views • 57 slides

Dr. Atef A. Mahmoud , MD, FRCP Professor of Internal Medicine & Rheumatology

Management of Refractory cases of Osteoporosis. Dr. Atef A. Mahmoud , MD, FRCP Professor of Internal Medicine & Rheumatology Cairo Unversity. Case Study. F.M.A,84 years old Egyptian F., MRN 707962 Rheumatology OPD: (December 1977, 67yrs old)

609 views • 47 slides

New treatment targets in osteoporosis

Dept. of Pathophysiology School of Medicine. National University of Athens Greece. New treatment targets in osteoporosis. Gourzi Vassiliki PhD Candidate. Bone remodeling. Physiological process < bone tissue continuously renewed Bone resorption Osteoclasts Bone formation osteoblasts.

1.04k views • 33 slides

Androgen Deprivation Therapy and Bone Loss in Men With Prostate Cancer

Androgen Deprivation Therapy and Bone Loss in Men With Prostate Cancer. William K. Oh, MD Associate Professor of Medicine Harvard Medical School Clinical Director, Lank Center for GU Oncology Dana-Farber Cancer Institute Boston, Massachusetts. Osteoporosis.

606 views • 27 slides

Alendronate improves bone mineral density in HIV-infected children and adolescents IMPAACT P1076

Alendronate improves bone mineral density in HIV-infected children and adolescents IMPAACT P1076. Denise L. Jacobson, Jane C. Lindsey, Hans Spiegel, Rohan Hazra, George Siberry, for the IMPAACT P1076 Study Team. Team members have no conflicts of interest to disclose.

475 views • 26 slides

345 views • 26 slides

The Female Athlete Triad

The Female Athlete Triad. Ann M. Heaslett, M.D. Psychiatrist, Madison, WI USA Member USA 100K Team 2002-5. The Female Athlete Triad?. What is the Female Athlete triad?. Disordered Eating Amenorrhea Osteoporosis. The Female Athlete Triad. Originally described in 1992

601 views • 24 slides

The Female Athlete Triad

The Female Athlete Triad. Ann M. Heaslett, M.D. Psychiatrist, Madison, WI USA Member USA 100K Team 2002-5. The Female Athlete Triad?. What is the Female Athlete triad?. Disordered Eating Amenorrhea Osteoporosis. The Female Athlete Triad. Originally described in 1992

497 views • 24 slides

252 views • 24 slides

Allergan, Inc. NDA 21-701 tazarotene 1.5 and 4.5 mg capsules

Allergan, Inc. NDA 21-701 tazarotene 1.5 and 4.5 mg capsules. Backup slides presented FDA Advisory Committee July 12, 2004. Prior and Concomitant Therapy. Patients were not to have used:

379 views • 18 slides

American Nuclear Society Biology and Medicine Division

American Nuclear Society Biology and Medicine Division. Presentation to the ANS Board of Directors Elisabete De Nadai Fernandes, Chair November 12, 2008, Reno, Nevada. BMD Mission.

305 views • 16 slides

American Nuclear Society Biology & Medicine Division

American Nuclear Society Biology & Medicine Division. Presentation to the ANS Board of Directors by Rolf Zeisler, Chair-Elect Albuquerque, NM. History and Mission of BMD.

269 views • 14 slides

157 views • 4 slides

136 views • 2 slides

Introduction:

79 views • 1 slides